Ocugen Inc (OCGN) Stock
Fundamentals
Recent news

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
OCGN

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
OCGN

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGN

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
OCGN
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
OCGN

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
OCGN

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
OCGN

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
OCGN

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN

Ocugen Q2 Earnings Call Highlights
Ocugen Q2 Earnings Call Highlights
OCGN

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
OCGN

Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
OCGN

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
OCGN

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
OCGN
About Ocugen Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 1964 |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | 1982 |
| Ms. Rita Johnson-Greene M.B.A. | CFO & Principal Accounting Officer | 1977 |
| Mr. Paul Staid | Executive Vice President of Operations | — |
| John Kouch J.D. | General Counsel | — |
| Mr. Chris Clark | VP of Corporate Communications | — |
| Ms. Kristen Craft | Head of People & Culture | — |
| Dr. Vijay Tammara Ph.D. | Chief Development Officer | 1960 |
| Dr. Mohamed Genead M.D., M.Sc. | Chief Medical Officer | — |
| Ms. Jyothy Pillai M.S. | VP & Head of Regulatory & Quality | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +5.3 | +69.6 | -54.6 | -24.5 | ||||||||
| 2022 | -24.8 | -9.0 | -7.6 | -33.6 | +1.3 | +4.6 | +6.6 | +2.4 | -32.1 | -3.4 | -8.2 | -14.5 |
| 2023 | +1.6 | -21.3 | -15.0 | -17.4 | -34.3 | +20.0 | +10.7 | -28.3 | -7.0 | -7.5 | +8.3 | +45.0 |
| 2024 | -18.2 | +77.4 | +70.8 | -14.3 | +24.5 | -8.8 | +15.3 | |||||
| 2026 | +12.4 | -3.4 | -23.3 | +11.7 | -16.9 | +6.4 | -23.3 |



